Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-26 @ 10:36 AM
Ignite Modification Date:
2025-12-26 @ 10:36 AM
NCT ID:
NCT04736628
Pre Assignment Details:
Patients underwent a screening period of up to 3 weeks from the time of informed consent. After confirmation of eligibility at screening, patients continued in a 2-week baseline run-in period. Patients who successfully completed the screening and baseline run-in periods and met the inclusion/exclusion criteria were randomised equally into 1 of 3 parallel dose groups, and in each dose group to treatment either with avenciguat or matching placebo in a 3:1 ratio.
Recruitment Details:
This trial was a Phase II, randomised, placebo-controlled, double-blind (within dose groups), parallel, multicentre clinical trial in patients with non-diabetic kidney disease (non-DKD) to demonstrate the effectiveness and safety of avenciguat and to characterize the dose-response relationship for avenciguat in patients with non-DKD by assessing 3 doses and placebo.
Study:
NCT04736628
Study Brief:
Results Section:
NCT04736628